Does combination drug therapy improve compliance of the neurogenic bladder?
In this highly selected group of patients with neurogenic bladder dysfunction and poor bladder compliance combination medical therapy with 2 or 3 drugs improved compliance, decreased bladder pressures at capacity and improved clinical outcomes. Combination therapy requires further study of the side effect profile but these results suggest that it should be considered for patients in whom antimuscarinic agents alone fail.
Plasma miR-21 may be a novel biomarker for the diagnosis of AMI. Our study may also provide implications for the development of new biomarkers.